ArticleNeurology(R) neuroimmunology & neuroinflammation2020
Neuromyelitis optica spectrum disorders with unevenly clustered attack occurrence.
Article in Neurology(R) neuroimmunology & neuroinflammation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSD.Multiple sclerosis (Houndmills, Basingstoke, England) · 2021Trial
- Safety and Effectiveness of Inebilizumab in Patients with Neuromyelitis Optica Spectrum Disorder: Interim Analysis of a Post-marketing Surveillance in Japan.Neurology and therapy · 2026Article
- Switching from complement inhibitors in AQP4-IgG-positive NMOSD: clinical characteristics, an operational "cluster phase" and potential strategies to prevent therapeutic gaps.BMC neurology · 2026Article
- Substrates of 8.5-year clinical outcomes in aquaporin-4 IgG-positive neuromyelitis optica spectrum disorders.Journal of neurology · 2026Article
- Meningococcal prophylaxis in neurological diseases treated with complement inhibitors: an expert consensus for Germany, Austria, and Switzerland.Therapeutic advances in neurological disorders · 2026Review
- Relapses during treatment with monoclonal antibodies targeting B-cells in NMOSD.Journal of neurology · 2025Article
- Outcomes and predictors of relapse and severe pneumonia in Chinese patients with AQP4-IgG-positive neuromyelitis optica spectrum disorder receiving inebilizumab: a prospective cohort study.Frontiers in immunology · 2025Article
- Usage status of biologics for the chronic treatment of optic neuritis in neuromyelitis optica spectrum disorders in Japan.Japanese journal of ophthalmology · 2025Article
- Interleukin-6 Signaling Blockade Induces Regulatory Plasmablasts in Neuromyelitis Optica Spectrum Disorder.Neurology(R) neuroimmunology & neuroinflammation · 2024Article
- Characterizing mortality in patients with AQP4-Ab+ neuromyelitis optica spectrum disorder.Annals of clinical and translational neurology · 2024Article
- Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management.Journal of neurology · 2024Review
- Satralizumab as a treatment for pediatric-onset neuromyelitis optica spectrum disorder with cluster attack: a case report.Journal of neurology · 2023Article
- A Clinical Approach to Existing and Emerging Therapeutics in Neuromyelitis Optica Spectrum Disorder.Current neurology and neuroscience reports · 2023Review
- Results of a Survey on Diagnostic Procedures and Treatment Choices for Neuromyelitis Optica Spectrum Disorder in Korea: Beyond the Context of Current Clinical Guidelines.Journal of clinical neurology (Seoul, Korea) · 2022Article
- Relapse After Cessation of Immunosuppressants in Seropositive Neuromyelitis Optica Spectrum Disorder With Long-Term Remission.Journal of clinical neurology (Seoul, Korea) · 2021Article
- Impact of comorbid Sjögren syndrome in anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorders.Journal of neurology · 2021Article
- Neuromyelitis Optica Spectrum Disorder Treatment-Current and Future Prospects.International journal of molecular sciences · 2021Review
- Somatic symptoms with psychogenic or psychiatric background: Characteristics and pitfalls.Journal of family medicine and primary care · 2021Article
- Therapeutic Response and Possible Biomarkers in Acute Attacks of Neuromyelitis Optica Spectrum Disorders: A Prospective Observational Study.Frontiers in immunology · 2021Observational
- A window into the future? MRI for evaluation of neuromyelitis optica spectrum disorder throughout the disease course.Therapeutic advances in neurological disorders · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe aim of this study was to elucidate the characteristics of clinical attacks in neuromyelitis optica spectrum disorders (NMOSDs) with positive serum anti-aquaporin-4 antibody. Both the timing and sequential pattern of clinical types were analyzed.
methodsA total of 69 patients with NMOSD were enrolled in this study, all of whom were treated at a single university hospital. All data regarding the clinical attacks (including types and date) together with other clinical information were collected.
resultsAnalysis of clinical attacks from the enrolled patients showed that there were 2 distributional patterns of attack occurrence in each patient: (1) "clustered" occurrences, which occurred within 12 months from the previous attack, and (2) "nonclustered" intermittent occurrences, which occurred ≥12 months after the previous attack. These occurrences were regardless of the duration from the onset. During the "clustered" period, clinical attacks were more likely to show a similar clinical manifestation, such as optic neuritis or myelitis. After entering the "nonclustered" intermittent period, the relapses were of random clinical type, regardless of the previous clinical manifestation.
conclusionsPatients with NMOSD showed mixed periods of "clustered" occurrence with frequent attacks presenting with similar manifestations and "nonclustered" intermittent periods with sparse relapses. Approximately half of the relapses occurred during the "clustered" period within 12 months of the last clinical attack. Clinicians should pay special attention to whether the patients are presently in the "clustered" or "nonclustered" period to decide optimal relapse-preventive strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.